Hua Medicine (the "Company", HKEx stock code: 2552) announced today that the Company and its wholly-owned subsidiary, Nanjing AscendRare Pharmaceutical Technology Co., Ltd.(AscendRare), presented a number of basic research findings at the 84th American Diabetes Association (ADA) Annual Scientific Sessions.
Hua Medicine (the "Company", HKEx stock code: 2552) announced today that its wholly owned subsidiary Nanjing AscendRare Pharmaceutical Technology Co., Ltd.
Hua Medicine (the "Company", HKEx: 2552.HK) announced that the Company has officially initiated its Phase I clinical trial of its 2nd generation glucokinase allosteric activator (2nd Gen GKA) in the United States, with the successful enrollment of the first patient.
ir@wzjhad.com
No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203
沪公网安备 31011502013809号 Privacy Statement Terms of Use
